Lianjun Xing

Lianjun Xing


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JLJunqiu Li
Junqiu Li
JPJielu Pan
Jielu Pan
DXDinghong Xiao
Dinghong Xiao
NSNan Shen
Nan Shen
RWRuiqing Wang
Ruiqing Wang
LXLianjun Xing
Lianjun Xing
Background: Previous literature has explored the relationship between chronic atrophic gastritis (CAG) and isolated cancers within the upper gastrointestinal cancers; However, an integrative synthesis across the totality of upper gastrointestinal cancers was conspicuously absent. The research objective was to assess the relationship between CAG and the risk of incident upper gastrointestinal cancers, specifically including gastric cancer, oesophageal cancer, and oesophagogastric junction cancer.Methods: Rigorous systematic searches were conducted across three major databases, namely PubMed, Embase and Web of Science, encompassing the timeline from database inception until August 10, 2023. We extracted the necessary odds ratio (OR) and their corresponding 95% confidence interval (CI) for subsequent meta-analysis. Statistical analyses were conducted using Stata 17.0 software.Results: This meta-analysis included a total of 23 articles encompassing 5858 patients diagnosed with upper gastrointestinal cancers. CAG resulted in a statistically significant 4.12-fold elevated risk of incident gastric cancer (OR = 4.12, 95% CI 3.20–5.30). Likewise, CAG was linked to a 2.08-fold increased risk of incident oesophageal cancer (OR = 2.08, 95%CI 1.60–2.72). Intriguingly, a specific correlation was found between CAG and the risk of incident oesophageal squamous cell carcinoma (OR = 2.29, 95%CI 1.77–2.95), while no significant association was detected for oesophageal adenocarcinoma (OR = 0.62, 95%CI 0.17–2.26). Moreover, CAG was correlated with a 2.77-fold heightened risk of oesophagogastric junction cancer (OR = 2.77, 95%CI 2.21–3.46). Notably, for the same type of upper gastrointestinal cancer, it was observed that diagnosing CAG through histological methods was linked to a 33–77% higher risk of developing cancer compared to diagnosing CAG through serological methods.Conclusion: This meta-analysis indicated a two- to fourfold increased risk of gastric cancer, oesophageal cancer, and oesophagogastric junction cancer in patients with CAG. Importantly, for the same upper gastrointestinal cancer, the risk of incident cancer was higher when CAG was diagnosed histologically compared to serological diagnosis. Further rigorous study designs are required to explore the impact of CAG diagnosed through both diagnostic methods on the risk of upper gastrointestinal cancers.

1 July 2021 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
NSNan Shen
Nan Shen
JPJielu Pan
Jielu Pan
HMHongyu Miao
Hongyu Miao
HZHaiyan Zhang
Haiyan Zhang
LXLianjun Xing
Lianjun Xing
XYXiao Yu
Xiao Yu
Background: This meta-analysis aimed to evaluate the effectiveness of fibrates in the treatment of pruritus in patients with primary biliary cholangitis (PBC), so as to guide the clinical treatment of such cases. Methods: Searches of the PubMed, Google Scholar, and Cochrane Library databases were performed to identify randomized controlled trials (RCTs) and prospective studies published up to December 2020 that used bezafibrate and fenofibrate as treatments for pruritus in patients with PBC. Data extraction and quality evaluation of the included literature were performed. Review Manager 5.3 software was employed for statistical analysis of the data. Results: This meta-analysis included 7 studies, comprising 382 patients with PBC, which assessed the efficacy of bezafibrate and fenofibrate for treating pruritus. The results showed that treatment with fibrates significantly improved pruritus symptoms in patients with PBC [relative risk (RR) =6.52, 95% confidence interval (CI): 3.26–13.06, P<0.00001]. Subgroup analysis revealed that in comparison with fenofibrate (RR =5.34, 95% CI: 0.88–32.62, P=0.07), bezafibrate (RR =25.87, 95% CI: 7.93–84.42, P<0.00001) was more effective in improving pruritic symptoms in patients with PBC. Bezafibrate was also superior to fenofibrate in reducing the degree of pruritus in patients (mean difference =3.36, 95% CI: 2.62–4.09, P=0.05, I2=73%). Conclusions: Fibrates can significantly improve pruritus symptoms in patients with PBC but only in a subset of patients. Further studies are needed to elucidate the pathophysiological mechanisms underlying the effect of fibrates on pruritus in PBC, and thus guide future treatment regimens.

1 January 2021 in Pharmaceutical Biology
Verified
Journal Article
Open access
XYXiao Yu
Xiao Yu
HZHaiyan Zhang
Haiyan Zhang
JPJielu Pan
Jielu Pan
LZLu Zou
Lu Zou
LTLing Tang
Ling Tang
LXLianjun Xing
Lianjun Xing
Jiang Zhi Granule (JZG) is known to improve hepatic function, reduce liver fat deposition and inflammation in non-alcoholic fatty liver disease (NAFLD).To determine the protective mechanism of JZG ...

3 January 2023 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
LTLing Tang
Ling Tang
XYXiao Yu
Xiao Yu
LZLu Zou
Lu Zou
SLShaobin Li
Shaobin Li
YCYanqi Cheng
Yanqi Cheng
HFHong Fang
Hong Fang
Background. Qinggan Huoxue recipe (QGHXR), a traditional Chinese medicinal formula, has a protective effect against liver fibrosis. However, the underlying mechanisms remain unclear. Objective. This study investigated the antifibrotic role of QGHXR and its underlying mechanisms. Methods. The composition of QGHXR was determined using ultra performance liquid chromatography‐tandem mass spectrometry (UPLC‐MS/MS). Female C57BL/6J mice were fed either a Lieber–DeCarli liquid diet or pair‐fed control diet and intraperitoneally injected with CCl4 for 8 weeks (n = 8). In week 5, the mice were administered 100, 200, and 400 mg/kg QGHXR via oral gavage daily for 4 weeks. Results. UPLC‐MS result showed that QGHXR contained 45 compounds including salvianolic acid A, scutellarin, baicalin, rutin, and chai saponin D. QGHXR alleviated pathological alterations in the liver. The alanine aminotransferase (ALT) level was reduced to 44.88 ± 4.39 U/L, aspartate aminotransferase (AST) to 76.25 ± 4.17 U/L, alkaline phosphatase (ALP) to 60.75 ± 5.41 U/L, and acetaldehyde to 38.54 ± 1.01 U/L compared with that of the control group (ALT 72.38 ± 5.19 U/L, AST 119.63 ± 9.82 U/L, and ALP 98.63 ± 6.71 U/L and acetaldehyde 64.86 ± 4.70 U/L). QGHXR inhibited lipid overproduction and fibrotic gene expression. The serum concentration of chemokine C‐X‐C ligand 16 (CXCL16) was reduced to 62.83 ± 6.80 pg/ml compared with that of the control group (130.91 ± 13.72 pg/mL). QGHXR downregulated CXCL16 mRNA and protein expressions. Pharmacological CXCL16 treatment reversed the QGHXR‐induced protective effects in ethanol plus CCl4 fed mice. QGHXR reduced CXCL16 levels (91.97 ± 5.86 pg/ml) in LPS‐stimulated RAW264.7 cells compared with that of the control group (148.68 ± 8.62 pg/ml) and inhibited toll‐like receptor 4 and nuclear factor‐kappa B phosphorylation. Conclusions. This study demonstrated that QGHXR mitigates experimental alcoholic liver fibrosis by CXCL16 inhibition, and may be considered a potential therapeutic agent for treating liver fibrosis.

21 October 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YFYuchen Fang
Yuchen Fang
LXLianjun Xing
Lianjun Xing
Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by hepatic steatosis, hepatocellular injury and inflammation, while fibrosis staging provides additional prognostic information (EASL-EASD-EASO, 2024). Wogonoside (WOG), a flavonoid from Scutellaria baicalensis, has been reported to ameliorate liver injury, dyslipidemia, inflammation and oxidative stress in mice with nonalcoholic fatty liver disease (NAFLD) (Jiang et al., 2020), providing a rationale for further investigation. We read the study with interest by Wang et al. (2026), which examined WOG in high-fat and high-fructose diet (HFFD)-fed mice and free fatty acid (FFA)-treated HepG2 cells. Its integration of metabolic phenotyping, histology, transcriptomics and erastin/ferrostatin-1 experiments provides valuable preclinical evidence. The authors proposed that WOG alleviates MASH partly by suppressing ferroptosis through the xCT/GPX4 axis, based on reduced lipid peroxidation and Fe 2+ accumulation alongside increased xCT and GPX4 expression. Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation (Mishima et al., 2025). However, this study shows evidence that WOG attenuates ferroptosis-associated biochemical changes, but does not establish that WOG provides protection against ferroptosis. We would like to highlight several points that may help to refine the interpretation of the ferroptosis findings, further characterize the histological response, and improve the clarity of the report.All figures mentioned below, including supplementary figures, refer to the results published in the original study by Wang et al. (2026). In Figure 7, WOG treatment under FFA + erastin challenge reduced lipid peroxide (LPO) levels (Figure 7B) and Fe²⁺ levels (Figure 7D), and increased xCT and GPX4 expression (Figures 7N and7O). Together, these results provide meaningful evidence that WOG attenuates biochemical changes closely associated with ferroptosis. Ferroptosis is, however, a form of regulated cell death. Lipid peroxidation, iron accumulation, glutathione depletion, and altered xCT/GPX4 expression are important mechanistic indicators, but they do not independently establish that ferroptosis occurred. Recent expert recommendations emphasize convergent evidence, including cell-death assessment, rescue by ferroptosis inhibitors, measurement of lipid peroxidation and evaluation of alternative cell-death pathways (Mishima et al., 2025). This study did not report viability or death under the FFA + erastin challenge or assess whether WOG or Fer-1 rescued any resulting cell death. Supplementary Figure S1 evaluates WOG's cytotoxicity at the selected concentrations, but does not establish whether FFA or erastin induced death. Thus, the current findings support attenuation of a ferroptosis-associated biochemical phenotype, while protection against ferroptosis remains to be established. One way to validate this finding is to combine the existing Liperfluo assay, or an alternative probe such as C11-BODIPY 581/591, with propidium iodide (PI)-or SYTOX-based cell-death measurements and a complementary viability endpoint. Assessing whether WOG rescues measured death, alongside Fer-1 and an additional inhibitor such as liproxstatin-1, would further support that WOG directly inhibits ferroptosis. In Figure 7H, the bracketed comparison appears to indicate lower LPO levels in the FFA + Fer-1 + WOG group than in the FFA + Fer-1 group. This warrants clarification given the text's description of a "similar, non-additive effect". In addition, the figure legend defines asterisks as comparisons with the FFA group, whereas the brackets appear to indicate other pairwise comparisons.Clarifying these comparisons and the basis for the non-additive interpretation would improve the consistency between the figure and text.The HFFD model reproduced metabolic and hepatic abnormalities relevant to MASH. H&E and Oil Red O images support steatosis, while TNF-α immunohistochemistry supports inflammatory signaling. However, no standardized NAFLD Activity Score (NAS), Steatosis, Activity and Fibrosis (SAF) component scores or blinded pathological evaluation were reported. TNF-α staining cannot substitute for assessment of lobular inflammation, and hepatocellular ballooning was not quantified. Blinded assessment of steatosis, lobular inflammation and ballooning, using criteria appropriate to the experimental model, would better define disease activity and treatment response (Kleiner et al., 2005). Activity scores should support, rather than replace, morphological evaluation of steatohepatitis. Neither collagen-specific staining, such as Sirius Red or Masson's trichrome, nor fibrosis staging was reported. Assessing the presence and extent of fibrosis would help characterize the model and clarify the scope of WOG's effects. However, HFFD models may develop limited fibrosis, and collagen staining might reveal only mild changes. Both the absence of fibrosis assessment and the model's potential limitations should therefore be considered when evaluating the evidence for WOG's antifibrotic effects.A few numerical discrepancies appear to warrant clarification. Figures 3B and3C indicate differentially expressed gene (DEG) totals of 535 (333 + 202) and 335 (162 + 173), whereas the text and Figure 3D indicate 540 and 381, respectively. The intersection is reported as 129 genes in the text but 138 in Figure 3D. The most straightforward explanation is a reporting or typographical error, if so, this would not affect the underlying analyses. A more consequential possibility is that filtering or annotation inconsistencies affected the input gene lists, potentially altering overlap or enrichment results and their mechanistic interpretation. Reconciling the counts, input gene lists and selection criteria for each analysis would clarify whether correction of the presentation alone is sufficient. To support the description of...